Consolidated revenue from operations climbed by 16% to ₹195.69 crore, up from ₹168.92 crore in the same quarter last year. Additionally, consolidated earnings before interest, tax, depreciation, and amortisation (EBITDA) rose by 22% to ₹43.29 crore from ₹35.47 crore a year earlier, with the EBITDA margin improving to 22.1% from 21.0%.
The company’s revenue from operations increased by 15.8% year-on-year to ₹195.7 crore, while EBITDA experienced a growth of 17.9% to ₹48.0 crore. The EBITDA margin was up by 40 basis points to 24.5%, driven by operational discipline amid a challenging external landscape.
ALSO READ | RPG Life Sciences anticipates API rebound to drive growth, with margins expected to remain stable
During the quarter, the domestic formulations segment grew by 14.8%, surpassing the 11.6% growth of the Indian pharmaceutical market. The firm attributed its performance to a focus on key therapies, new product launches, and effective field force utilization.
RPG Life Sciences has now entered the Top 50 Indian pharmaceutical companies as of June 2026, becoming the fifth-fastest-growing firm in the Indian pharmaceutical sector.
The international formulations sector achieved a growth of 7.7% for the quarter, while the active pharmaceutical ingredients (API) segment saw a substantial 35.6% increase, bolstered by a unit returning to operations.
The company also reported a 16% growth in its Naprosyn brand during the quarter, with key therapy areas like nephrology and rheumatology recording double-digit growth.
ALSO READ | RPG Life Sciences Q4 Results: Strong operating performance, base quarter effects impacting profit
Ashok Nair, Managing Director of RPG Life Sciences Ltd, stated, “We have commenced FY27 on a positive note, continuing our history of market-outpacing performance and growth. Our Domestic Formulations business has consistently outperformed the market and facilitated our entry into the Top 50 ranking in the Indian Pharma Market, marking a significant milestone in our growth trajectory.
Looking ahead, we will focus on enhancing our international presence through market expansion and onboarding new customers, along with scaling our API operations to drive the next growth wave. With a solid balance sheet, strong profitability, and ongoing investment in talent, we are confident in maintaining our growth momentum over the long term.”
Shares of RPG Life Sciences Ltd closed at ₹2,895.95, down by ₹22.60, or 0.77%, on the BSE.
ALSO READ | RPG Life aims for ₹100 crore sales from the pain relief drug Naprosyn in the next two years
